Trials / Unknown
UnknownNCT00673218
The Effect of Xolair on Inhibiting Leukotriene and Cytokine (IL-4 and IL-13) Release From Blood Basophils
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- Sponsor
- Creighton University · Academic / Other
- Sex
- All
- Age
- 19 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
If you are allergic to ragweed, and not taking certain medications, you will be asked to have blood drawn. We will perform experiments on your blood cells.
Detailed description
Adult ragweed allergic subjects will have blood drawn. Basophils will be enriched and stimulated with allergen and controls. Supernatants from these stimulations will be assayed for cytokines and histamine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Placebo, Q2 or 4 weeks depending on Ige level and weight as appropriate for active treatment. |
| DRUG | Xolair | 150 to 375 mg is administered SC every 2 or 4 weeks |
Timeline
- Start date
- 2007-06-01
- Primary completion
- 2012-11-01
- Completion
- 2012-11-01
- First posted
- 2008-05-07
- Last updated
- 2012-07-06
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00673218. Inclusion in this directory is not an endorsement.